에키리움(EQ) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 에키리움(EQ)?

에키리움(EQ) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of EQ?

The market cap of EQ is approximately $156M, ranking 4,291 within its sector.

Q: What is the 52-week high and low for EQ?

EQ has recorded a 52-week high of $3.54 and a low of $0.37.

Equillium Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$2.46

-0.03 ▼ -1.20%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$2.35

-0.11 ▼ -4.47%

에키리움(EQ) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$156M

스몰캡

P/E

배당수익률

없음

52주 위치

66%

저점 +565% · 고점 -31%

애널리스트

적극 매수

B-

Fundamental health

vs. 성장주 초소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 55%

밸류에이션

데이터 부족

재무 안정

Top 33%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.32	Insider Own ⓘ	20.43%	Shs Outstand ⓘ	63.2M	Perf Week ⓘ	-0.4%
Market Cap ⓘ	0.16B	Forward P/E ⓘ	-	EPS next Y ⓘ	-8.1%	Insider Trans ⓘ	-6.47%	Shs Float ⓘ	50.3M	Perf Month ⓘ	-16.61%
Enterprise Value ⓘ	0.09B	PEG ⓘ	-	EPS next Q ⓘ	-0.05	Inst Own ⓘ	57.06%	Short Float ⓘ	11.07%	Perf Quarter ⓘ	13.89%
Income ⓘ	-0.02B	P/S ⓘ	-	EPS this Y ⓘ	40.17%	Inst Trans ⓘ	13.6%	Short Ratio ⓘ	6.99	Perf Half Y ⓘ	93.7%
Sales ⓘ	0.00B	P/B ⓘ	2.61	EPS next 5Y ⓘ	8.32%	ROA ⓘ	-47.75%	Short Interest ⓘ	5.57M	Perf YTD ⓘ	58.71%
Book/sh ⓘ	0.94	P/C ⓘ	2.54	EPS past 3/5Y ⓘ	40.45% 23.22%	ROE ⓘ	-54.39%	52W High ⓘ	-30.51% ($3.54)	Perf Year ⓘ	510.88%
Cash/sh ⓘ	0.97	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-31.9%	52W Low ⓘ	564.86% ($0.37)	Perf 3Y ⓘ	230.87%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	18.25%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	8.75% 9.62%	Perf 5Y ⓘ	-57.88%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-100%	Oper. Margin ⓘ	-	ATR (14) ⓘ	0.26	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	18.62	EPS Q/Q ⓘ	77.3%	Profit Margin ⓘ	-	RSI (14) ⓘ	41.5	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	18.62	Sales Q/Q ⓘ	-	SMA20 ⓘ	-11.75% ($2.79)	Beta ⓘ	1.83	Target Price ⓘ	$8.56
Payout ⓘ	-	Debt/Eq ⓘ	0.01	Earnings ⓘ	2026/5/13	SMA50 ⓘ	-9.78% ($2.73)	Rel Volume ⓘ	0.35	Prev Close ⓘ	$2.49
Employees ⓘ	14	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	-31.29% -	SMA200 ⓘ	33.31% ($1.85)	Avg Volume(3M) ⓘ	0.80M	Price ⓘ	$2.46
IPO ⓘ	2018/10/12	Option/Short ⓘ	Yes/Yes			Trades ⓘ	2008	Volume ⓘ	278,639	Change ⓘ	-1.2%

Quarterly earnings trend SEC filings · USD

24.3

24.6

24.9

24.12*

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 - · 순이익 $-5M (YoY +39%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Equillium Inc (EQ) Investment Analysis

What kind of company is Equillium Inc?

에키리움(EQ) 성장주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 Equillium is a US clinical-stage biotechnology company that targets immune and inflammatory diseases. Its core candidate is the monoclonal antibody itolizumab, which has a differentiated mechanism that modulates signaling pathways of immune cell surface receptors to suppress pathogenic T effector cells while preserving regulatory T cells. The company is centered around a novel drug pipeline that has primarily been developed for immune-mediated diseases such as graft-versus-host disease.

Learn more about Equillium Inc →

Market Cap

$0.2B

Approx. KRW 0.2 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4291

Employees14people

IPO2018/10/12

Current Price$2.46 ≈ 3,370원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 13일 (수) · 장 마감 후 EPS -31.3%

🔔 Earnings release 2026년 3월 25일 (수) · 장 마감 후 EPS +33.3%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-54.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-47.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-31.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.01

✓ Very low debt

My positionTop 25%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

18.62

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

18.62

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$8.56

현재가 대비 +248.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-8.1%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+8.3%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+0.2%

평균 서프라이즈

2026.05.13

하회

실적 $-0.06 · 예상 $-0.04 -36.4%

2026.03.25

상회

실적 $-0.04 · 예상 $-0.06 +36.8%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+40.2%

양호

My positionMid-range

Low range Average High range

성장주 초소형주 Median 21.2% · Top 30%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-8.1%

부진

My positionBottom 25%

Low range Average High range

성장주 초소형주 Median 13.9% · Bottom 15%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+8.3%

매우 부진

My positionBottom 5%

Low range Average High range

성장주 초소형주 Median 21.6% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+40.5%

양호

My positionMid-range

Low range Average High range

성장주 초소형주 Median 24.8% · Top 27%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+23.2%

양호

My positionMid-range

Low range Average High range

성장주 초소형주 Median 12.0% · Top 32%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -126%p below the market

EQ -57.9% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-126.2%p

Significantly behind the market

vs Health Care (XLV)

-82.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

+494.9%p

well ahead of the market

vs Health Care (XLV)

+491.2%p

well ahead of the sector average

Rank among peers

5-year return Top among peers Based on 245 peers

1-year return Top among peers Based on 315 peers

Current position within 52-week range

Low (-564.9%p) High (-30.5%p)

Current price is 564.9% above the 52-week low and 30.5% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-32.0%

Annualized volatility

95.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $2.46 below the midline ($2.79). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.069 < Signal -0.027 in negative zone + Hist negative (-0.042). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 41.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 12.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Mid-range

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

2.61x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 1.35x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$8.56 vs. current price +248.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow shows some pressure

Insider modest net selling -6.5% · Institutional net buying +13.6% · Short interest elevated 11.1% · Short interest up +6.3pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-6.5%

Insiders net selling

🏦 Institutions (funds & investors)

+13.6%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 57.1%

Adequate institutional weight

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 20.4%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 22.5%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

11.1%

Somewhat high

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +6.3%p increase

Short interest days to cover

7.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 63.2M주

Float (tradable shares) 50.3M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding EQ

ETFs with the highest weightings · 3 total shown

DFAS

Dimensional U.S. Small Cap ETF

0.00%

$15.2B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
EQ This Stock	$155.5M	-	2.6 ▲	-54.39% ▼	-	-1.2%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

Derivative ETFs for EQ

Leveraged, inverse, and covered call ETFs based on the underlying asset

24 derivative ETFs based on EQ (Leverage 8 · Inverse 8 · Covered Call 8)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

⚠️ Caution: Long-Term Holding

Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.

📈 Leverage 8 ETFs that move 2-3x with EQ (high volatility)